| Views | |
|---|---|
| Pharmacoepidemiologic and clinical rationale for the inclusion of L-arginine and dihydroquercetin in the combined pharmacotherapy of hypertensive patients with COVID-19 | 30 |
| June 2025 | July 2025 | August 2025 | September 2025 | October 2025 | November 2025 | December 2025 | |
|---|---|---|---|---|---|---|---|
| Pharmacoepidemiologic and clinical rationale for the inclusion of L-arginine and dihydroquercetin in the combined pharmacotherapy of hypertensive patients with COVID-19 | 0 | 0 | 1 | 12 | 3 | 13 | 1 |
| Views | |
|---|---|
| Naletova_Pharmacoepidemiologic_25.pdf | 6 |
| Views | |
|---|---|
| Canada | 10 |
| United States | 6 |
| Argentina | 1 |
| United Kingdom | 1 |
| Indonesia | 1 |
| Vietnam | 1 |
| Views | |
|---|---|
| Ottawa | 9 |
| Mountain View | 3 |
| Sacramento | 2 |
| Los Angeles | 1 |
| Suipacha | 1 |
| Warrington | 1 |